Abstract
Background
Poorly differentiated thyroid cancer (PDTC) is biologically more aggressive. Surgery remains the mainstay of treatment. The utility of radioactive iodine (RAI) after surgery is unclear.
Methods
In this retrospective study, patients treated between Jan 2012 and Dec 2017 were included. The demographic, clinical and treatment-related details, including RAI ablation, were recorded and their survival analyzed.
Results
Thirty-five patients fulfilled the eligibility criteria. Majority was treatment naïve at presentation. All patients underwent surgery followed by RAI ablation, with a cumulative median dose of 220 mCi (range 40–1140). Sixteen patients received more than one radioiodine treatment for distant metastases. Incomplete resection, age > 45 years and the presence of distant metastasis influenced survival the most. The 3-year PFS of patients with PDTC was 69%.
Conclusion
All patients in our series showed uptake and responded to treatment. Further use of molecular markers and functional molecular imaging would better our understanding of this entity.
Similar content being viewed by others
References
Lin JD, Chao TC, Hsueh C (2007) Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. Clin Endocrinol 66:224–228
Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849–1855
Carcangiu ML, Zamp G, Rosai J (1984) Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde Struma”. Am J Surg Pathol 8:655–668
DeLellis RA, World Health Organization, International Agency for Research on Cancer (2004) Pathology and genetics of tumours of endocrine organs. 3rd ed. Lyon: IARC Press, Chapter 2, Poorly differentiated carcinoma, p. 73–6.
Volante M, Collini P, Nikiforov YE, Sobrinho-simoes M, Kakudo K, Katoh R et al (2007) Poorly differentiated thyroid carcinoma: the turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31(8):1256–1264
Xu B, Ibrahimpasic T, Wang L, Sabra MM, Migliacci JC, Tuttle RM et al (2016) Clinicopathologic features of fatal non-anaplastic follicular cell-derived thyroid carcinomas. Thyroid 26(11):1588–1597
Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM (2017) Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity. Eur Thyroid J 6(4):187–196
Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW (2007) An evidence-based review of poorly differentiated thyroid cancer. World J Surg 31(5):934–945
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
Sadow PM, Faquin WC (2012) Poorly differentiated thyroid carcinoma: an incubating entity. Front Endocrinol (Lausanne) 3:77
Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A et al (2006) Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106(6):1286–1295
Yu MG, Rivera J, Jimeno C (2017) Poorly differentiated thyroid carcinoma: 10-year experience in a southeast asian population. Endocrinol Metab 32:288–295
Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR et al (2014) Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab 99:1245–1252
Cherkaoui GS, Guensi A, Taleb S, Idir MA, Touil N, Benmoussa R et al (2015) Poorly differentiated thyroid carcinoma: a retrospective clinicopathological study. Pan Afr Med J 21:137
Tanaka K, Sonoo H, Saito W, Ohta Y, Shimo T, Sohda M et al (2011) Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma. ISRN Endocrinol 2011:308029
Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A et al (2004) Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100:950–957
Saglietti C, Onenerk AM, Faquin WC, Sykiotis GP, Ziadi S, Bongiovanni M (2017) FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature. Cytopathology 28(6):467–474
Kane SV, Sharma TP (2015) Cytologic diagnostic approach to poorly differentiated thyroid carcinoma: a single-institution study. Cancer Cytopathol 123(2):82–91
Jung TS, Kim TY, Kim KW, Oh YL, Park DJ, Cho BY et al (2007) Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J 54:265–274
Nunes da Silva T, Limbert E, Leite V (2018) Poorly differentiated thyroid carcinoma patients with detectable thyroglobulin levels after initial treatment show an increase in mortality and disease recurrence. Eur Thyroid J 7(6):313–318
Acknowledgements
I would like to acknowledge Dr. Manish Mair and Dr. Burhanuddin N Qayyumi for their contribution toward this study and Atanu Bhatacharjee, Section of Biostatistics, Centre for Cancer Epidemiology, Homi Bhabha National Institute (HBNI), Tata Memorial Centre, Mumbai, Maharashtra, India.
Funding
None.
Author information
Authors and Affiliations
Contributions
Study concepts: ST, DC, DN. Study design: ST, HD, DN. Data acquisition: AY, YM, RS, HD. Quality control of data and algorithms: ST, AP, SK. Statistical analysis: AB, ST. Manuscript preparation: ST, HD, SGL, SB, DC. Manuscript editing: ST, SGL, SB, DC. Manuscript reviewing: all authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Institute ethical committee clearance was taken for this study (Approval number: IEC/1219/3314/001, Project number-3314). All patients received the standard of care for their condition as per the ethical standards.
Informed consent
No identifying information about participants is available in the article. However, all patients have given consent for the treatment they have received.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Thiagarajan, S., Yousuf, A., Shetty, R. et al. Poorly differentiated thyroid carcinoma (PDTC) characteristics and the efficacy of radioactive iodine (RAI) therapy as an adjuvant treatment in a tertiary cancer care center. Eur Arch Otorhinolaryngol 277, 1807–1814 (2020). https://doi.org/10.1007/s00405-020-05898-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-020-05898-9